1. Apparatus, comprising:
a plurality of system components, wherein at least one of the plurality of system components is coupled to an antenna; and
a management entity, wherein the management entity includes a system-side antenna coupled to the management entity to receive wireless signals from the antenna of the at least one of the plurality of system components.
2. The apparatus of claim 1, further comprising:
an external management network to receive a signal sent from the management entity.
3. The apparatus of claim 2, wherein the signal is a wireless signal.
4. The apparatus of claim 2, wherein the management entity is to receive a wireless signal from the external management network.
5. The apparatus of claim 1, wherein the antenna of the at least one of the plurality of system components is integral to the at least one of the plurality of system components to send performance signals and to receive control signals.
6. The apparatus of claim 2, wherein the management entity is to control at least one performance aspect of at least one of the plurality of system components.
7. The apparatus of claim 2, further comprising:
a bus coupled to the plurality of system components configured to send and receive bus signals from the plurality of system components.
8. Apparatus comprising:
a plurality of server devices, wherein at least one of the plurality of server devices includes at least one system component, wherein the at least one system component includes an integral antenna to transmit information regarding at least one performance aspect of the at least one system component; and a management entity to receive performance signals from the at least one system component and to transmit control signals to the at least one system component; and
at least one sensor, wherein the at least one sensor includes an antenna coupled to the at least one sensor to send and receive a signal.
9. The apparatus of claim 8, further comprising:
a wireless access point to receive a plurality of wireless signals, wherein the plurality of wireless signals includes at least one of the following:
a signal from the management entity; and
the signal from the at least one sensor.
10. The apparatus of claim 9, further comprising:
a management network communicatively coupled to the wireless access point.
11. The apparatus of claim 10, wherein the management network is to receive signals, analyze the received signals and transmit signals configured to cause an alteration of at least one performance aspect of at least one of the following:
at least one of the plurality of server devices;
the at least one sensor; and
at least one climate control device.
12. The apparatus of claim 8, wherein the plurality of computing devices includes a plurality of rack-mounted servers.
13. The apparatus of claim 8, wherein the at least one sensor includes at least one equipment sensor.
14. The apparatus of claim 8, further comprising:
at least one multiplexing device coupled to the management entities of the plurality of server devices to receive a plurality of signals from the management entities and to combine the plurality of signals into a single signal and wirelessly transmit the single signal.
15. The apparatus of claim 14, further comprising:
a management network communicatively coupled to the wireless access point.
16. The apparatus of claim 15, wherein the multiplexing device is to receive signals from the management entities and send a single wireless signal to the management network.
17. A method, comprising:
receiving a plurality of signals from a plurality of management entities coupled to a plurality of system components, at least one of which includes an antenna to transmit a performance related signal to a system-side antenna coupled to the management entity;
multiplexing the plurality of signals; and
transmitting the multiplexed signal to a management network.
18. The method of claim 17, further comprising:
analyzing the multiplexed signal; and
determining the relative health of the plurality of system components based on the analyzed multiplexed signal.
19. The method of claim 17, further comprising:
receiving a signal from a management network;
demultiplexing the signal into a plurality of signals, at least one of which is addressed to at least one of the plurality of management entities; and
sending the plurality of signals to the at least one of the plurality of management entities.
20. A machine readable medium having machine executable instructions contained therein, which when executed perform the following operations:
receiving a plurality of signals from a plurality of management entities coupled to a plurality of system components, at least one of which includes an antenna to transmit a performance related signal to a system-side antenna coupled to the management entity;
multiplexing the plurality of signals; and
transmitting the multiplexed signal to a management network.
21. The machine readable medium of claim 20, further comprising:
analyzing the multiplexed signal; and
determining the relative health of the plurality of system components based on the analyzed multiplexed signal.
22. The machine readable medium of claim 20, further comprising:
receiving a signal from a management network;
demultiplexing the signal into a plurality of signals, at least one of which is addressed to at least one of the plurality of management entities; and
sending the plurality of signals to the at least one of the plurality of management entities.
23. Apparatus comprising:
one or more system components, at least one of which is coupled to an antenna, wherein the antenna is to transmit and receive bus signals and to transmit and receive management signals; and
a management entity, further comprising a system-side antenna to send and receive management signals.
24. The apparatus of claim 23, further comprising:
a management network to receive a signal transmitted from a management-side antenna of the management entity.
25. The apparatus of claim 23, wherein the management entity is configured to analyze the received management signals and determine the relative health of the at least one system component.
26. The apparatus of claim 25, wherein the management entity is configured to send a management signal configured to alter at least one performance aspect of the at least one system component based on the determined relative health.
27. A system, comprising:
a plurality of system components, wherein at least one of the plurality of system components is coupled to an antenna;
a management entity, wherein the management entity further comprises a system-side antenna coupled to the management entity to receive wireless signals from the antenna of the at least one of the plurality of system components;
at least one omni-directional antenna communicatively coupled to the management entity.
28. The system of claim 27, further comprising:
a management network to receive a wireless signal transmitted from the at least one omni-directional antenna.
29. The apparatus of claim 28, wherein the management network is to analyze the received signal and transmit a signal configured to cause an alteration of at least one performance aspect of the at least one of the plurality of system components.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I:
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I is limited to formula BB as follows:
K is C;
Y is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, or alkoxy;
R1 is
Rm at each occurrence is independently selected from hydrogen, halogen, nitro, cyano, hydroxyl, alkoxy, \u2014CO2(alkyl), \u2014C(O)N(alkyl)2, alkyl, heteroarylalkyl, arylalkyl, aryl, and heteroaryl;
R2 is elected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloalkenyl, monoalkylaminoalkyl, dialkylaminoalkyl, cycloheteroalkylalkyl, hydroxyaryl, aryloxyalkyl, alkoxyalkyl, hydroxyalkyl, or a heterocyclic ring;
R is independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, aryl, arylalkyl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, cyanoalkyl, aminoalkyl, hydroxyalkyl, aryloxyalkyl, hydroxyaryl or NR1R2, wherein R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloalkenyl, monoalkylaminoalkyl, dialkylaminoalkyl, cycloheteroalkylalkyl, hydroxyaryl, aryloxyalkyl, alkoxyalkyl, hydroxyalkyl, or a heterocyclic ring;
Ra is hydrogen, halo, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, heteroarylaminocarbonyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, hydroxyaryl, alkoxyalkyl, aryloxyalkyl, nitro, amino, CHO, CO2 alkyl, CONReRf, CH2NRgRh, CO2H, CH2OH, CH2NRH, NRgRh, NHCH2Rg, NHCHRgRh, NHCORe, NHCONReRf or NHSO2ReRf;
Rb is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, halo, heteroarylaminocarbonyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, nitro, amino, CHO, CO2 alkyl, hydroxyaryl, aryloxyalkyl, CONRiRj, CH2NRkRl, CO2H, CH2OH, CH2NHRk, NHCH2Rk, NRkRl, NHCHRkRl, NHCORi, NHCONRiRj or NHSO2Ri;
Rq and Rw are the same or different and are independently selected from hydrogen, halo, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, heteroarylaminocarbonyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, hydroxyaryl, aryloxyalkyl, nitro, amino, CHO, CO2 alkyl, CONReRf, CH2NRgRh, CO2H, CH2OH, CH2NHRg, NRgRh, NHCH2Rg, NHCHRgRh, NHCORe, NHCONReRf, NHSO2ReRf, \u2550O, \u2550S, SRi, NHNRkRl, NHNRkCO2Ri, NHSO2Ri or a heterocyclic ring;
where Re and Rf are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and Re and Rf can be taken together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;
Rg and Rh are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and Rg and Rh can be taken together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;
Ri and Rj are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and Ri and Rj can be taken together with the nitrogen to which they are attached to form a 5-, 6-or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;
Rk and Rl are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and Rk and Rl can be taken together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S; and
Rc and Rd are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, hydroxy, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, hydroxyaryl, or aryloxyalkyl; or
Rc and Rd may optionally be taken together with the carbon to which they are attached to form a 3- to 7-membered ring which may optionally include an O atom or an N atom.
2. A compound as defined in claim 1, or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where R is hydrogen, alkyl or hydroxyalkyl;
Ra is selected from hydrogen, halo, alkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONReRf,NRgRhor CH2NRgRh;
Rb is selected from hydrogen, halo, alkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONRiRj, NRkRl, or CH2NRkRl;
Rq is hydrogen, halo, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, CN, NO2, NH2, CHO, CO2alkyl, CONReRf, NRgRh, or CH2NRgRh;
Rw is hydrogen, hydroxy, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,cyano, halo, nitro, amino, \u2550O, \u2550S, SRi, CHO, CO2 alkyl, CONRiRj, CH2NRkRl, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring;
Rc and Rd are the same or different and are independently selected from hydrogen, alkyl, or hydroxy; and
Y is selected from hydrogen, halo, or alkyl.
3. A compound as defined in claim 2, or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or alkyl; Ra is hydrogen; Rb is independently hydrogen or alkyl; Rc and Rd are each hydrogen; and Y is hydrogen or alkyl.
4. A compound as defined in claim 1 or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, wherein
R is hydrogen, alkyl, or hydroxyalkyl;
Rb is selected from hydrogen, halo, alkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONRiRj, NRk or CH2NRkRl;
Rq is hydrogen, halo, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONReRf, NRgRh or CH2NRgRh;
Rw is hydrogen, hydroxy, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cyano, halo, nitro, amino, \u2550O, \u2550S, SRi, CHO, CO2 alkyl, CONRiRj, CH2NRkRl, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and
Y is selected from hydrogen, halo or alkyl.
5. A compound as defined in claim 4, or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, wherein
R is hydrogen or alkyl;
Rb is selected from hydrogen, halo, alkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONRiRj, NRkRl or CH2NRkRl;
Rq is hydrogen, halo, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, CN, NO2, NH2, CHO, CO2 alkyl, CONReRf, NRgRh or CH2NRgRh; and
Rw is hydrogen, hydroxy, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cyano, halo, nitro, amino, \u2550O, \u2550S, SRi, CHO, CO2 alkyl, CONRiRj, CH2NRkRl, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring.
6. A compound as defined in claim 5, or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, wherein
R is alkyl;
Rb is hydrogen or alkyl;
Rq is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl;
Rw is hydrogen, hydroxy, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and
Y is hydrogen or alkyl.
7. A compound having the structure
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is alkyl; Rb is hydrogen or alkyl; Rq is hydrogen, alkyl, or arylalkyl; Rw is hydroxy, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and X is aryl, arylalkyl, alkyl, heteroaryl, or heteroarylalkyl; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is alkyl; Rb is hydrogen or alkyl; Rq is hydrogen, alkyl, or arylalkyl; Rw is hydroxy, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and Xa is aryl, arylalkyl, alkyl, heteroaryl, heteroarylalkyl or halo; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is alkyl; Rb is hydrogen or alkyl; Rq is hydrogen, alkyl, or arylalkyl; Rw is hydroxy, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and Xb is aryl, arylalkyl, alkyl, heteroaryl, heteroarylalkyl or halo; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C;
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where W is S or NH; K is C; R is alkyl; Rb is H, alkyl, nitro, formyl, CO2alkyl, amino, halo, and CN; Rq is hydrogen, alkyl, or arylalkyl; Rw is hydroxy, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and Xa is aryl, arylalkyl, alkyl, heteroaryl, heteroarylalkyl or halo;
T is a cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl ring, each ring substituted by 0-4 R5 and 0-1 R6;
R3 and R4 are independently at each occurrence hydrogen, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cyano, nitro, NReRf, or CHO provided that if M is CRm, X is S, and either of R3 and R4 is alkyl, alkenyl, or alkynyl, then the other of R3 and R4 is not alkyl, alkenyl, or alkynyl;
or R3 and R4 combine to form \u2550O or a \u2550C, wherein the carbon of \u2550C is substituted by hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, substituted amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl; and
R5 and R6 are, independently at each occurrence, hydrogen, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, heteroarylaminocarboyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, hydroxyaryl, aryloxyalkyl, nitro, oxo, NReRf, CHO, CO2 alkyl, hydroxyaryl, aryloxyalkyl, CONReRf, CH2NReRf, CO2H, CH2OH, CH2NHC(O)ReRf, NHCORi, NHCONReRf, NHSOpRi, \u2014SO2NReRf, NReSO2NReRf, or NReSOpRi;
or R5 and R6 located on adjacent atoms can be taken together to form an optionally substituted cycloalkyl, aryl, heteroaryl, or cycloheteroalkyl ring.
8. A compound as defined in claim 7 having the structure
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is CH3; Rb is hydrogen or CH3; Rq is hydrogen, CH3, C2H5, or benzyl; Rw is hydroxy, \u2550O, \u2550S, SCH3, NHC3H7, NHNH(C6H5), NHNHCO2C2H5 or dioxolanyl; and X is 1-naphthyl, 1-(4-methyl)naphthyl, 1-(4-fluoro)naphthyl, 1-(6-methoxy)naphthyl, benzyl, or phenyl, t-butyl; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is CH3; Rb is hydrogen or CH3; Rq is hydrogen, CH3, C2H5, or benzyl; Rw is hydroxy, \u2550O, \u2550S, SCH3, NHC3H7, NHNH(C6H5), NHNHCO2C2H5 or dioxolanyl; and Xa is phenyl, benzyl, t-butyl, 1-naphthyl, 1-(4-fluoro)naphthyl, benzthiophen-3-yl, 1-(4-methyl)naphthyl, 1-(2-methoxy)naphthyl, 1-(6-methoxy)naphthyl, 3-fluorophenyl, 4-fluorophenyl, 3-methylphenyl, 2-chlorophenyl, 1-(4-methoxy)naphthyl, 1-(4-bromo)naphthyl, 1-(4-iodo)naphthyl, 5-anthracenyl, 1-anthracenyl, 4-quinolin-1-yl 2-quinolin-1-yl, 1-(4-cyano)naphthyl, 5-iodo, 4-benzthiophenyl, 1-(2-hydroxy)naphthyl, 1-(6-hydroxy)naphthyl, 1-(4-hydroxy)naphthyl; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is CH3; Rb is hydrogen or CH3; Rq is hydrogen, CH3, C2H5, or benzyl; Rw is hydroxy, \u2550O, \u2550S, SCH3, NHC3H7, NHNH(C6H5), NHNHCO2C2H5 or dioxolanyl; and Xb is phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,5-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-pyridyl, 2-(4-pyridyl)ethyl, 2-(4-imidazolyl)ethyl, 3-chloro-4-methoxyphenyl, 3-hydroxy-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 4-methyl-3-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2,3-dimethoxyphenyl, 4-chlorophenyl, 2-napthyl, 3-chlorophenyl, 3,4-dichlorophenyl, 4-azidophenyl, 2,4-dimethoxyphenyl, 3-ethoxyphenyl, 3-(methylthio)phenyl, 4-(methylthio)phenyl, 3-(acetylenyl)phenyl, 4-methoxy-3-pyridyl, 3-cyanophenyl, 2-methyl-4-methoxyphenyl, 3-azidophenyl, 3-methyl-isothiazolyl, 1-methyl-pyrazol -5-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where K is C; R is CH3; Rb is hydrogen or CH3; R1 is hydrogen, CH3, C2H5, or benzyl; Rw is hydroxy, \u2550O, \u2550S, SCH3, NHC3H7, NHNH(C6H5), NHNHCO2C2H5 or dioxolanyl; and Xc is hydrogen, CH3, or F; or
or all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, where W is S or NH; K is C; R is alkyl; Rb is H, C1-4alkyl, halo, and CN; Rq is hydrogen, alkyl, or arylalkyl; Rw is hydroxy, \u2550O, \u2550S, SRi, NRkRl, NHNRkRl, NHNRkCO2Ri, or a heterocyclic ring; and Xa is aryl, arylalkyl, alkyl, heteroaryl, heteroarylalkyl or halo; W is S or NH; Q is CH;
T is a phenyl, naphthyl, pyrimidyl, pyridinyl, pyridazinyl, piperazinyl, thiophenyl, thiazolyl, isoxazolyl, or imidazolyl ring;
R3 is hydrogen, halogen, or hydroxy; and
R4 is hydrogen, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cyano, nitro, NReRf, or CHO;
or R3 and R4 combine to form \u2550O or a double bond, wherein the double bond is substituted by hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, substituted amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, or cycloalkylalkyl;
R5 and R6 are independently at each occurrence:
(a) hydrogen, bromo, chloro, fluoro, C1-4alkyl, arylalkyl, OR7, oxo, NO2, cyano, NH2, \u2014NHC1-4alkyl, \u2014N(C1-4alkyl)2, SO2C1-4alkyl, \u2014NHC(O)C1-4alkyl, \u2014C(O)N(C1-4alkyl)2, \u2014C(O)NH(C1-4alkyl), \u2014C(O)NH2, CO2H, \u2014CO2(C1-4alkyl), arylalkyl; or
(b) a phenyl, naphthyl, pyrazolyl, pyrimidinyl, pyridinyl, isoxazolyl, indolyl, or morpholinyl ring; each of which is optionally further substituted by 1-3 R8;
or R5 and R6 located on adjacent atoms can be taken together to form a dioxole or phenyl ring, where each ring is optionally further substituted;
R7 at each occurrence is selected from hydrogen, C1-4alkyl, (CH2)vC(O)NH2, (CH2)vheteroaryl, (CH2)vO(CH2)yO(CH2)zOR9, (CH2)vN(C1-4alkyl)2,(CH2)vheterocycloalkyl, or (CH2)vphenyl;
R8 is halogen, oxo, NH2, hydroxy, C1-4alkyl, C1-4alkoxy, \u2014(CH2)aryl, or heterocycloalkyl;
R9 is hydrogen or C1-4alkyl;
and
v, y and z are independently at each occurrence selected from 0, 1 or 2.
9. A compound having the structure
including all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, where K is C; Y is H or CH3; R is CH3, C2H5 or 2-hydroxyethyl; Rb is hydrogen or CH3; and one of R1 and R2 is H and the other of R1 and R2 is benzothiazol-2-yl, alkylbenzothiazol-2-yl, alkoxybenzothiazol-2-yl, halobenzothiazol-2-yl, thiazol-2-yl, 4-(1-naphthyl)thiazol-2-yl, 2-quinolin-1-yl, or a thiazole which is optionally substituted with heteroarylthio, heteroaryl, dialkyl, alkyl, aryl where the aryl may be optionally substituted with halo, alkyl, nitro, hydroxy, alkoxy, dialkoxy, carboxy, alkylaminocarbonyl, arylaminocarbonyl, hydroxyalkylaminocarbonyl, cycloheteroalkylcarbonyl, alkoxyalkylaminocarbonyl, heteroarylaminocarbonyl.
10. The compound as defined in claim 9, having the structure
including all stereoisomers thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, where Xa is 4,5-dimethyl, 5-chloro, 4-methyl, 5-methyl, 4-phenyl, 4-(1-naphthyl), 4-(2-naphthyl), 4-(4-fluoronaphth-1-yl), 4-(4-methylnaphth-1-yl), 4-(3-nitrophenyl), 4-(6-hydroxynaphth-1-yl), 4-(1,2,4-triazol-5-yl)thiomethyl, 4-benzoic acid, 4-(4-bromonaphth-1-yl), 4-(N-ethyl) benzamide, 4-(N-2-methoxyphenyl)benzamide, 4-(N-methyl-N-2-hydroxyethyl)benzamide, 4-(N-(pyrrolidinyl)benzamide, 4-(N-morpholinyl)benzamide, 4-(N-phenyl-N-methyl)benzamide, 3-(N-ethyl)benzamide, 3-(N-2-methoxyphenyl)benzamide, 3-(N-2-methoxyethyl)benzamide, 3-(N-methyl-N-2-hydroxyethyl)benzamide, 3-(N-methyl-N-phenyl)benzamide, 3-(N-4-acetylpiperaziny-1-yl) benzamide, 3-(N-3-methoxypropyl)benzamide, 2-(6-carboxy)pyridine, 3-(N-3-hydroxy-4-methoxyphenyl)benzamide, 3-(N-3-fluoro-4-methoxyphenyl)benzamide, 3-(N-2,3-dimethoxyphenyl)benzamide, 3-(N-3-dimethoxyphenyl)benzamide, 3-(N-5-trifluormethyl-1,3,4-thiadiazol-2-yl)benzamide, 3-(N-5-methyl-1,3,4-thiadiazol-2-yl)benzamide, 3-(N-5-chlorobenzoxazol-2-yl)benzamide, 3-(N-3-benzonitrile)benzamide, 3-(N-4-methoxypyrid-3-yl)benzamide, 5-(1,4-benzodioxane), 4-(1,3-benzodioxole).
11. The compound as defined in claim 1 having the structure:
(ii) stereoisomers of (i) thereof, or a pharmaceutically acceptable salt of (i) thereof.
12. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.
13. A pharmaceutical combination comprising a compound as defined in claim 1 and an immunosuppressant, an anticancer agent, an anti-viral agent, an anti-inflammatory agent, an anti-fungal agent, an anti-biotic, an anti-vascular hyperproliferation agent, an anti-depressant agent, a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent, a platelet aggregation inhibitor, andor an antiosteoporosis agent, wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR\u03b3 agonist, a PPAR \u03b1\u03b3 dual agonist, an SGLT2 inhibitor, a DP4inhibitor, an aP2inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin andor a meglitinide, wherein the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor agonist, an aP2 inhibitor andor an anorectic agent, wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor, wherein the antihypertensive agent is an ACE inhibitor, angiotensin II receptor antagonist, NEPACE inhibitor, calcium channel blocker andor \u03b2-adrenergic blocker.
14. The combination as defined in claim 13 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-262570, isaglitazone, JTT-501 , NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO 39242, GW-409544, KRP297, AC2993, LY315902, P3298 andor NVP-DPP-728A, wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, andor mazindol, wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, itavastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, niacin andor LY295427, wherein the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEPACE inhibitor which is omapatrilat, S(R*,R*)-hexahydro-6-(2-mercapto-1-oxo-3-phenylpropyl)amino-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat) or CGS 30440;
an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;
amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or clonidine HCl, wherein the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban;
the immunosuppressant is a cyclosporin, mycophenolate, interferon-beta, deoxyspergolin, FK-506 or Ant.-IL-2;
the anti-cancer agent is azathiprine, 5-fluorouracel, cyclophosphamide, cisplatin, methotrexate, thiotepa, or carboplatin;
the anti-viral agent is abacavir, aciclovir, ganciclovir, zidanocin, or vidarabine; and
the antiinflammatory drug is ibuprofen, celecoxib, rofecoxib, aspirin, naproxen, ketoprofen, diclofenac sodium, indomethacin, piroxicam, prednisone, dexamethasone, hydrocortisone, or triamcinolone diacetate.